Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
Unit of Ophthalmology, Valduce Hospital, Como, Italy.
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2717-2722. doi: 10.1007/s00417-021-05245-6. Epub 2021 May 29.
Extended depth-of-focus (EDOF) is a promising intraocular lens (IOL) technology for cataract surgery. The aim of the study was to report the real-life experience related to the implant of EDOF AcrySof® IQ Vivity® (Alcon Inc., USA) IOL.
The study was designed as a interventional, prospective, case series with 3 months of follow-up. Patients needing cataract surgery, without any other kind of ocular diseases, were recruited and implanted with AcrySof® IQ Vivity® IOL. We evaluated the refractive success of this IOL through complete ophthalmologic assessments and the administration of the Quality of Vision test. The main outcome measures were the refractive outcome; far, intermediate, and near vision; and Quality of Vision score.
We included 108 eyes (54 patients; age 62 ± 5 years). Intra-operative and post-operative complications were 0%. Thirty out of 100 eyes (28%) required toric IOL. Best-corrected visual acuity improved from 0.4 ± 0.3 LogMAR to 0.0 ± 0.0 LogMAR (p < 0.01). Refractive outcome was very good for far and intermediate visions, whereas a spherical addition of at least + 1.0D was required for near vision. The mean Quality of Vision score was of 15.5 ± 6.5. The most complained visual disturbances were haloes and glares, although resulting well-tolerated. Dynamic pupillometry findings well-correlated with the amount of complained post-operative visual discomforts.
AcrySof® IQ Vivity® IOL is a well-tolerated choice to correct far and intermediate vision. Spectacles are needed to optimize near vision. Our data strongly suggest dynamic pupillometry as a useful investigation to optimize post-operative refractive success.
扩展景深（EDOF）是白内障手术中一种很有前途的人工晶状体（IOL）技术。本研究旨在报告与植入 EDOF AcrySof® IQ Vivity®（Alcon Inc.，美国）IOL 相关的真实临床经验。
本研究设计为前瞻性、干预性、病例系列研究，随访时间为 3 个月。招募需要白内障手术且无其他眼部疾病的患者，并植入 AcrySof® IQ Vivity® IOL。我们通过全面的眼科评估和视力质量测试来评估该 IOL 的屈光效果。主要观察指标为屈光效果；远、中、近视力；以及视力质量评分。
共纳入 108 只眼（54 例患者；年龄 62±5 岁）。术中及术后无并发症。100 只眼中有 30 只（28%）需要植入散光 IOL。最佳矫正视力从 0.4±0.3 LogMAR 提高到 0.0±0.0 LogMAR（p<0.01）。远、中距离视力的屈光效果非常好，但近距视力需要至少+1.0D 的球镜附加。平均视力质量评分为 15.5±6.5。最常见的视觉障碍是光晕和眩光，但这些症状均能耐受。动态瞳孔测量结果与术后视觉不适的程度密切相关。
AcrySof® IQ Vivity® IOL 是一种可耐受的远、中距离视力矫正选择。为了优化近距视力，仍需要戴眼镜。我们的数据强烈表明，动态瞳孔测量是优化术后屈光效果的一种有用的检查方法。
